<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402882</url>
  </required_header>
  <id_info>
    <org_study_id>ISRCTN15088122</org_study_id>
    <nct_id>NCT01402882</nct_id>
  </id_info>
  <brief_title>Clinical Randomisation of an Antifibrinolytic in Significant Head Injury</brief_title>
  <acronym>CRASH-3</acronym>
  <official_title>Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: an International Randomised, Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CRASH-3 trial will provide reliable evidence about the effect of tranexamic acid on&#xD;
      mortality and disability in patients with traumatic brain injury. The effect of tranexamic&#xD;
      acid on the risk of vascular occlusive events and seizures will also be assessed.&#xD;
      Additionally, a nested study will be conducted in a subset of CRASH-3 trial participants.&#xD;
      This nested study (CRASH-3 Intracranial Bleeding Sub-Study [CRASH-3 IBS]) will examine the&#xD;
      effect of tranexamic acid on intracranial haemorrhage and cerebral ischaemia using CT Scans&#xD;
      in approximately 1,000 patients randomised into the CRASH-3 trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Worldwide, over 10 million people are killed or hospitalised because of traumatic&#xD;
      brain injury (TBI) each year. About 90% of deaths from TBI occur in low and middle income&#xD;
      countries. TBI mostly affects young adults and many experiencing long lasting or permanent&#xD;
      disability. The social and economic burden of TBI is considerable. Tranexamic acid (TXA) is&#xD;
      commonly given to surgical patients to reduce bleeding and the need for blood transfusion.&#xD;
      TXA has been shown to reduce the number of patients receiving a blood transfusion by about a&#xD;
      third, reduces the volume of blood transfused by about one unit, and halves the need for&#xD;
      further surgery to control bleeding in elective surgical patients. More recently, the CRASH-2&#xD;
      trial showed that the administration of TXA within 8 hours of injury significantly reduces&#xD;
      deaths due to bleeding (RR=0.85, 95% CI 0.76-0.96; p=0.008), and all-cause mortality&#xD;
      (RR=0.91, 95% CI 0.85-0.97; p=0.0035), with no apparent increase in vascular occlusive&#xD;
      events. A meta-analysis of randomised controlled trials of TXA in TBI showed a significant&#xD;
      reduction in haemorrhage growth (OR=0.61, 95%CI 0.41 to 0.91) and mortality (OR=0.59, 95%CI&#xD;
      0.35 to 0.99) with TXA. Although the results from these trials are promising, the estimates&#xD;
      are imprecise and there are no data on the effect of TXA on disability. Additionally, a&#xD;
      nested study will be conducted in a subset of CRASH-3 trial participants. This nested study&#xD;
      (CRASH-3 Intracranial Bleeding Sub-Study [CRASH-3 IBS]) will examine the effect of tranexamic&#xD;
      acid on intracranial haemorrhage and cerebral ischaemia using CT Scans in approximately 1,000&#xD;
      patients randomised into the CRASH-3 trial.&#xD;
&#xD;
      AIM: The CRASH-3 trial will provide reliable evidence about the effect of tranexamic acid on&#xD;
      mortality and disability in patients with TBI. The effect of TXA on the risk of vascular&#xD;
      occlusive events and seizures will also be assessed.&#xD;
&#xD;
      PRIMARY OUTCOME: The primary outcome is death in hospital (within 28 days of injury) of&#xD;
      patients randomised within 3 hours of injury (cause of death will be described).&#xD;
&#xD;
      SECONDARY OUTCOMES:&#xD;
&#xD;
        1. Vascular occlusive events (myocardial infarction, stroke, pulmonary embolism, clinical&#xD;
           evidence of deep vein thrombosis)&#xD;
&#xD;
        2. In hospital disability assessed using the Disability Rating Scale and Patient Orientated&#xD;
           Outcome&#xD;
&#xD;
        3. Seizures&#xD;
&#xD;
        4. Neurosurgical intervention&#xD;
&#xD;
        5. Days in intensive care Other adverse events will be described&#xD;
&#xD;
      Other Outcome Measures: CRASH-3 IBS Primary outcome - the total volume of intracranial&#xD;
      haemorrhage after randomisation, adjusting for baseline haemorrhage volume.&#xD;
&#xD;
      Secondary outcome -&#xD;
&#xD;
        -  Frequency of progressive haemorrhage: number of patients with a post-randomisation CT&#xD;
           scan with total haemorrhage volume of more than 25% of the volume on the&#xD;
           pre-randomisation scan;&#xD;
&#xD;
        -  Frequency of delayed haemorrhage: number of patients with haemorrhage on the&#xD;
           post-randomisation CT scan when there was not one on the pre-randomisation scan;&#xD;
&#xD;
        -  New focal ischaemic lesions: ischaemic lesions which appear on the post-randomisation CT&#xD;
           scan but not on the pre-randomisation scan;&#xD;
&#xD;
        -  Total volume of intracranial bleeding in patients who undergo surgical evacuation of&#xD;
           haemorrhage after randomisation, adjusting for volume of baseline bleeding.&#xD;
&#xD;
      TRIAL DESIGN: A large, pragmatic, randomised, double blind, placebo controlled trial among&#xD;
      13,000 traumatic brain injury patients&#xD;
&#xD;
      DIAGNOSIS AND INCLUSION/EXCLUSION CRITERIA:&#xD;
&#xD;
      Adults with traumatic brain injury who&#xD;
&#xD;
        -  are within eight hours of injury&#xD;
&#xD;
        -  with any intracranial bleeding on CT scan or who have a GCS of 12 or less, and&#xD;
&#xD;
        -  have no significant extra-cranial haemorrhage The fundamental eligibility criterion is&#xD;
           the responsible clinician's 'uncertainty' as to whether or not to use tranexamic acid in&#xD;
           a particular patient with traumatic brain injury.&#xD;
&#xD;
      TEST PRODUCT, REFERENCE THERAPY, DOSE AND MODE OF ADMINISTRATION: A loading dose of&#xD;
      tranexamic acid&#xD;
&#xD;
      (1 gram by intravenous injection) or placebo (sodium chloride 0.9%) will be given as soon as&#xD;
      possible after randomisation. A maintenance dose of tranexamic acid (1 gram by intravenous&#xD;
      injection) or placebo (sodium chloride 0.9%) will be given after the loading dose is&#xD;
      finished.&#xD;
&#xD;
      SETTING: This trial will be coordinated from the London School of Hygiene &amp; Tropical Medicine&#xD;
      (University of London) and conducted worldwide in hospitals in low, middle and high income&#xD;
      countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is death in hospital in patients recruited within 3 hours and cause of death will be described.</measure>
    <time_frame>within 28 days of injury</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(a) Vascular occlusive events (myocardial infarction, stroke, pulmonary embolism, clinical evidence of deep vein thrombosis)</measure>
    <time_frame>Prior death, discharge or 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(b) In hospital disability assessed using the Disability Rating Scale and Patient Orientated Outcome</measure>
    <time_frame>Prior death, discharge or 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(c) Seizures</measure>
    <time_frame>Prior death, discharge or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(d) Neurosurgical intervention</measure>
    <time_frame>prior death, discharge or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(e) Days in intensive care</measure>
    <time_frame>prior death, discharge or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(f) Other adverse events</measure>
    <time_frame>prior death, discharge or day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>CRASH-3 IBS: Primary outcome - the total volume of intracranial haemorrhage</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of progressive haemorrhage: number of patients with a post-randomisation CT scan with total haemorrhage volume of more than 25% of the volume on the pre-randomisation scan</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of delayed haemorrhage:</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New focal ischaemic lesions:</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>â€¢ Total volume of intracranial bleeding in patients who undergo surgical evacuation of haemorrhage after randomisation</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12737</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(Sodium Chloride 0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>2 grams (1 gram over 10 minutes and 1 gram over 8 hours)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tranexamic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adults with traumatic brain injury who&#xD;
&#xD;
          -  are within eight hours of injury (limited to within 3 hours from September, 2016)&#xD;
&#xD;
          -  with any intracranial bleeding on CT scan or who have a GCS of 12 or less, and&#xD;
&#xD;
          -  have no significant extra-cranial haemorrhage The fundamental eligibility criterion is&#xD;
             the responsible clinician's 'uncertainty' as to whether or not to use tranexamic acid&#xD;
             in a particular patient with traumatic brain injury&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as to&#xD;
        whether or not to use tranexamic acid in a particular patient with traumatic brain injury&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haleema Shakur</last_name>
    <role>Study Director</role>
    <affiliation>LSHTM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>High Technology Medical Center, University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <link>
    <url>http://crash3.lshtm.ac.uk/</url>
    <description>Trial website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>traumatic brain injury</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>antifibrinolytic</keyword>
  <keyword>randomised</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After all relevant publications are completed, totally anonymised data will be available at https://ctu-app.lshtm.ac.uk/freebird/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

